Ovid Therapeutics (OVID) Operating Income (2016 - 2026)
Ovid Therapeutics' (OVID) quarterly Operating Income came in at -$17.8 million in Q1 2026, down 42.2% YoY from -$30.9 million in Q1 2025, and down 45.17% on a QoQ basis from -$12.3 million in Q4 2025.
Ovid Therapeutics (OVID) Operating Income (2016 - 2026) Analysis & Trends
Ovid Therapeutics (OVID) has 11 years of Operating Income data on file, last reported at -$17.8 million in Q1 2026.
- Quarterly Operating Income fell 42.2% year-over-year to -$17.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$47.7 million (up 16.28% YoY) and the FY2025 annual result came in at -$42.4 million, up 31.42% from the prior year.
- Operating Income fell to -$17.8 million in Q1 2026, from -$12.3 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$5.1 million in Q2 2025 to a low of -$20.5 million in Q2 2024.
- A 5-year average of -$13.9 million and a median of -$13.2 million in 2024 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2022 — Operating Income sank 109.21% — and 2025, when it jumped 75.27%.
- Tracing OVID's Operating Income over 5 years: stood at -$12.2 million in 2022, then tumbled by 49.41% to -$18.2 million in 2023, then soared by 41.05% to -$10.7 million in 2024, then retreated by 14.65% to -$12.3 million in 2025, then sank by 45.17% to -$17.8 million in 2026.
- The last three Operating Income figures came in at -$17.8 million (Q1 2026), -$12.3 million (Q4 2025), and -$12.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Ovid Therapeutics | 385.37 Mn | 229.84 Mn | - | -17.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.85 Mn |
| Dec 31, 2025 | -12.29 Mn |
| Sep 30, 2025 | -12.52 Mn |
| Jun 30, 2025 | -5.07 Mn |
| Mar 31, 2025 | -12.55 Mn |
| Dec 31, 2024 | -10.72 Mn |
| Sep 30, 2024 | -13.23 Mn |
| Jun 30, 2024 | -20.52 Mn |
| Mar 31, 2024 | -17.42 Mn |
| Dec 31, 2023 | -18.19 Mn |
| Sep 30, 2023 | -12.03 Mn |
| Jun 30, 2023 | -14.17 Mn |
| Mar 31, 2023 | -14.89 Mn |
| Dec 31, 2022 | -12.17 Mn |
| Sep 30, 2022 | -12.80 Mn |
| Jun 30, 2022 | -14.30 Mn |
| Mar 31, 2022 | -16.27 Mn |
| Dec 31, 2021 | -26.35 Mn |
| Sep 30, 2021 | -11.68 Mn |
| Jun 30, 2021 | -14.31 Mn |